Skip to main content
Home
Loading...
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube

Menu top

  • Assistance

User account menu

  • Log in
Home

Main navigation

  • Home
  • Programme
Menu Login
Close

Main navigation mobile

  • Home
  • Programme

Menu top

  • Assistance
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
Filters
Filters Close
Poster topics
Poster available until
  • Until platform closure (14)
Poster categories
  • Thematic Poster Session (19)
keywords
Session Reference
  • L-TPS01 (10)
  • L-TPS02 (13)
  • L-TPS03 (5)
  • L-TPS04 (12)
  • L-TPS05 (10)
  • L-TPS06 (7)
  • L-TPS07 (8)
  • L-TPS08 (7)
  • L-TPS09 (10)
  • L-TPS10 (10)
  • L-TPS11 (10)
  • L-TPS12 (8)
  • L-TPS13 (8)
  • L-TPS14 (11)
  • L-TPS15 (6)
  • L-TPS16 (7)
  • L-TPS17 (9)
  • L-TPS18 (9)
  • L-TPS19 (6)
  • x L-TPS20 (7)
  • L-TPS21 (7)
  • L-TPS22 (9)
  • L-TPS23 (13)
  • L-TPS24 (10)
  • L-TPS25 (2)
  • TPS01 (9)
  • TPS02 (10)
  • TPS03 (6)
  • TPS04 (6)
  • TPS05 (10)
  • TPS06 (10)
  • TPS07 (6)
  • TPS08 (12)
  • TPS09 (12)
  • TPS10 (5)
  • TPS11 (6)
  • TPS12 (6)
  • TPS13 (10)
  • TPS14 (6)
  • TPS15 (4)
  • TPS16 (9)
  • TPS17 (8)
  • TPS18 (9)
  • TPS19 (9)
  • TPS20 (8)
  • TPS21 (10)
  • TPS22 (7)
  • TPS23 (8)
  • TPS24 (8)
  • TPS25 (5)
  • TPS26 (9)
  • TPS27 (12)
  • TPS28 (4)
  • TPS29 (5)
  • TPS30 (10)
  • TPS31 (5)
  • TPS32 (12)
  • TPS33 (12)
  • TPS34 (10)
  • TPS35 (7)
  • TPS36 (8)
  • TPS37 (10)
  • TPS38 (8)
  • TPS39 (10)
  • TPS40 (4)
  • TPS41 (10)
  • x TPS42 (12)
  • TPS43 (12)
  • TPS44 (9)
  • TPS45 (10)
  • TPS46 (6)
  • TPS47 (11)
  • TPS48 (7)
  • TPS49 (10)
  • TPS50 (5)
  • TPS51 (2)
  • TPS52 (8)
  • TPS53 (6)
  • TPS54 (8)
  • TPS55 (7)
  • TPS56 (10)
  • TPS57 (4)
  • TPS58 (4)
  • TPS59 (12)
  • TPS60 (9)
  • TPS61 (7)
  • TPS62 (10)
  • TPS63 (10)
  • TPS64 (12)
  • TPS65 (13)
  • TPS66 (7)
  • TPS67 (10)
  • TPS68 (5)
  • TPS69 (11)
  • TPS70 (8)
  • TPS71 (8)
  • TPS72 (10)
  • TPS73 (9)
  • TPS74 (8)
  • TPS75 (7)
  • TPS76 (9)
  • TPS77 (6)
  • TPS78 (12)
  • TPS79 (2)
  • TPS80 (8)
  • TPS81 (6)
  • TPS82 (5)
  • TPS83 (4)
  • TPS84 (7)
  • TPS85 (8)
  • TPS86 (11)
  • TPS87 (7)
  • TPS88 (8)
  • TPS89 (4)
  • TPS90 (4)
  • TPS91 (3)
19 results
Thumbnail

D3.230 - Type I Hypersensitivity Among Private Dental Practitioners: Clinical Manifestations and Associated Factors

Thumbnail

D3.220 - Real-World Management of Pediatric Allergic Diseases: A Nationwide Physician Survey among Allergists and Pediatric Allergists in Turkey

Thumbnail

D3.215 - Shifting patterns of mite sensitization in Southern Europe: Real-World diagnostic and immunotherapy practices in Spain and Portugal (MITE-WISE Project)

Thumbnail

D3.218 - When the sting is not the sensitizer: a vespid venom allergy case

Thumbnail

D3.223 - Crossroads of Venom and Bite: A case of Horsefly - Wasp Cross - reactive Anaphylaxis

Thumbnail

D3.225 - Two years Sublingual SQ-Grass Pollen Tablet Immunotherapy Combined with Dupilumab Induces Longterm Suppression of Immediate Cutaneous Allergen Sensitivity

Thumbnail

D3.229 - Comparison of mold sensitization profiles in children (2021 and 2025): impact of environmental deterioration during martial law

Thumbnail

D2.232 - Aquagenic Urticaria: High Atopic Comorbidity, Familial Aggregation, and Differential Water Reactivity

Thumbnail

D2.233 - Epidemiology, Patient Characteristics, and Treatment Responses of Chronic Urticaria in Türkiye: A Systematic Literature Review

Thumbnail

D2.237 - Patient-reported changes in urticaria activity after tattoo placement

Thumbnail

D2.238 - Bilastine fast onset and strong peripheral antihistaminic activity: comparison with oral second-generation antihistamines and intramuscular dexchlorpheniramine in histamine-induced wheal and flare models

Thumbnail

D2.239 - Oral and parenteral bilastine, fast onset and strong peripheral antihistaminic activity: comparison with oral second-generation antihistamines and intramuscular dexchlorpheniramine in wheal and flare models

Thumbnail

D2.241 - Successful Slow Desensitization to Niraparib Following Failed Olaparib Desensitization in a Patient with Ovarian Cancer

Thumbnail

D2.242 - Chronic Urticaria and Thyroid Disease: Analysis of Clinical, Laboratory Data and Therapeutic Response in the Mediterranean Area of Tarragona

Thumbnail

D2.243 - Impact of simultaneous skin clearance and itch relief with lebrikizumab in patients with atopic dermatitis: post-hoc analysis from ADvocate1/2

Thumbnail

D2.229 - Food Allergy in Ukrainian Children: Risk Factors, Early Allergen Introduction and Natural History

Thumbnail

D2.234 - Mimicry of delayed pressure urticaria. Clinical case reports

Thumbnail

D2.235 - Urticaria Voices: Patient-reported disease burden and treatment experiences in Chronic Spontaneous Urticaria in China - A real-world evidence study (UV in China)

Thumbnail

D2.236 - Alexithymia and Depression in Patients with Chronic Spontaneous Urticaria Treated with Omalizumab

Download the app
The congress at your fingertips

Available on

App Store Google Play
QR Code Download
Mobile App Schedule page
Mobile App Home page
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
© 2026 EAACI
Made with   by CYIM